The MSKai software provides AI-powered segmentation, labeling, and measurement tools for assessment of T2-weighted MRIs of the lumbar spine.
The Food and Drug Administration (FDA) has granted 510(k) clearance for MSKai software, which offers a variety of adjunctive artificial intelligence (AI) tools for evaluating lumbar spine magnetic resonance imaging (MRI).
Through assessment of T2-weighted MRI scans of the lumbar spine, the MSKai software provides pathology detection, anatomical segmentation, labeling, and measurements within seconds, according to MSKai, the developer of the software.
For adjunctive assessment of lumbar spine MRIs, the newly FDA-cleared MSKai software provides AI-powered pathology detection, anatomical segmentation and measurements within seconds, according to MSKai, the developer of the software. (Image courtesy of Adobe Stock.)
The company maintained that the MSKai software can facilitate pre-surgical authorizations as well as monitoring of post-intervention treatments.
"The FDA's decision confirms that MSKai meets rigorous safety and performance standards as a spine imaging tool," said Chip Wade, Ph.D., chief operating officer at MSKai. "We're proud to deliver a product that gives healthcare professionals enhanced capabilities in lumbar spine analysis while reinforcing the central role of expert clinical judgement."
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.